|
Name |
3alpha-Hydroxytauranin
|
Molecular Formula | C22H30O5 | |
IUPAC Name* |
2-[[(1S,4aR,6R,8aR)-6-hydroxy-5,5,8a-trimethyl-2-methylidene-3,4,4a,6,7,8-hexahydro-1H-naphthalen-1-yl]methyl]-3-hydroxy-5-(hydroxymethyl)cyclohexa-2,5-diene-1,4-dione
|
|
SMILES |
C[C@]12CC[C@H](C([C@@H]1CCC(=C)[C@@H]2CC3=C(C(=O)C(=CC3=O)CO)O)(C)C)O
|
|
InChI |
InChI=1S/C22H30O5/c1-12-5-6-17-21(2,3)18(25)7-8-22(17,4)15(12)10-14-16(24)9-13(11-23)19(26)20(14)27/h9,15,17-18,23,25,27H,1,5-8,10-11H2,2-4H3/t15-,17-,18+,22+/m0/s1
|
|
InChIKey |
BJEQCQQYHRYXQG-CTWQGKMFSA-N
|
|
Synonyms |
3alpha-Hydroxytauranin; 1012335-00-0
|
|
CAS | NA | |
PubChem CID | 24800191 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 374.5 | ALogp: | 2.9 |
HBD: | 3 | HBA: | 5 |
Rotatable Bonds: | 3 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 94.8 | Aromatic Rings: | 3 |
Heavy Atoms: | 27 | QED Weighted: | 0.516 |
Caco-2 Permeability: | -5.434 | MDCK Permeability: | 0.00000513 |
Pgp-inhibitor: | 0.142 | Pgp-substrate: | 0.723 |
Human Intestinal Absorption (HIA): | 0.012 | 20% Bioavailability (F20%): | 0.96 |
30% Bioavailability (F30%): | 0.534 |
Blood-Brain-Barrier Penetration (BBB): | 0.038 | Plasma Protein Binding (PPB): | 97.51% |
Volume Distribution (VD): | 1.839 | Fu: | 2.50% |
CYP1A2-inhibitor: | 0.075 | CYP1A2-substrate: | 0.347 |
CYP2C19-inhibitor: | 0.054 | CYP2C19-substrate: | 0.303 |
CYP2C9-inhibitor: | 0.374 | CYP2C9-substrate: | 0.82 |
CYP2D6-inhibitor: | 0.112 | CYP2D6-substrate: | 0.254 |
CYP3A4-inhibitor: | 0.125 | CYP3A4-substrate: | 0.192 |
Clearance (CL): | 10.207 | Half-life (T1/2): | 0.691 |
hERG Blockers: | 0.009 | Human Hepatotoxicity (H-HT): | 0.071 |
Drug-inuced Liver Injury (DILI): | 0.025 | AMES Toxicity: | 0.237 |
Rat Oral Acute Toxicity: | 0.182 | Maximum Recommended Daily Dose: | 0.931 |
Skin Sensitization: | 0.855 | Carcinogencity: | 0.024 |
Eye Corrosion: | 0.009 | Eye Irritation: | 0.894 |
Respiratory Toxicity: | 0.958 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC003214 | 0.753 | D04VIS | 0.429 | ||||
ENC002490 | 0.735 | D0S0NK | 0.317 | ||||
ENC002494 | 0.706 | D0D2VS | 0.279 | ||||
ENC002172 | 0.453 | D0R7JT | 0.272 | ||||
ENC001621 | 0.429 | D06XMU | 0.272 | ||||
ENC002492 | 0.396 | D0L2LS | 0.269 | ||||
ENC000956 | 0.369 | D0IX6I | 0.265 | ||||
ENC002941 | 0.368 | D0D1SG | 0.265 | ||||
ENC002748 | 0.367 | D0KR5B | 0.265 | ||||
ENC005461 | 0.360 | D0IL7L | 0.265 |